IL2 and acute respiratory distress syndrome: The ongoing clinical trials (ClinicalTrials.gov Identifier: NCT04357444) will explore the efficacy of low-dose IL-2 in SARS-CoV-2-related ARDS, in the hope of providing clinically feasible treatment for SARS-CoV-2-related ARDS.